DeluzioT. Regarding inaccuracies in “What Options Are Available When Considering Starting Insulin: Premix or Basal?”Diabetes Technol Ther, 2012; 14:196–197.
2.
LaverniaF. What options are available when considering starting insulin: premix or basal?Diabetes Technol Ther, 2011; 13,Suppl 1:S-85–S-91.
3.
Correction. Diabetes Technol Ther, 2011; 13:980.
4.
KleinO, LyngeJ, EndahlL, DamholtB, NosekL, HeiseT. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab, 2007; 9:290–299.
BilzS, MeienbergF, FlueckigerM, FalconnierC, KellerU, PuderJ. Comparison of the pharmacodynamic, pharmacokinetic profiles of insulin detemir, insulin glargine in severely obese type 2 diabetic subjects [abstract]The Endocrine Society's 90th Annual Meeting. San Francisco: Endocrine Society, 2008OR 56-2.
7.
BolliGB, LucidiP, PorcellatiF, FanelliCG. Pivotal role of timely basal insulin replacement after metformin failure in sustaining long-term blood glucose control at a target in type 2 diabetes. Diabetes Care, 2011; 34,Suppl 2:S220–S224.
8.
PorcellatiF, RossettiP, RicciNB, PampanelliS, TorloneE, CamposSH, AndreoliAM, BolliGB, FanelliCG. Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes. Diabetes Care, 2007; 30:1261–1263.
9.
LeahyJ, CefaluWT. Insulin Therapy. New York: Marcel Dekker, 2002.
